Optipharm.CO.LTD (153710) - Total Liabilities
Based on the latest financial reports, Optipharm.CO.LTD (153710) has total liabilities worth ₩15.37 Billion KRW (≈ $10.42 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Optipharm.CO.LTD - Total Liabilities Trend (2015–2025)
This chart illustrates how Optipharm.CO.LTD's total liabilities have evolved over time, based on quarterly financial data. See Optipharm.CO.LTD (153710) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Optipharm.CO.LTD Competitors by Total Liabilities
The table below lists competitors of Optipharm.CO.LTD ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kolon Industries Inc
KO:120115
|
Korea | ₩3.71 Trillion |
|
Rockhaven Resources Ltd
V:RK
|
Canada | CA$3.60 Million |
|
Hong Yi Fiber Industry Co Ltd
TW:1452
|
Taiwan | NT$163.20 Million |
|
Lexibook Linguistic Electronic System SA
PA:ALLEX
|
France | €30.78 Million |
|
Silvano Fashion Group AS
WAR:SFG
|
Poland | zł12.73 Million |
|
Purple Innovation Inc
NASDAQ:PRPL
|
USA | $332.13 Million |
|
Athanase Innovation AB
ST:ATIN
|
Sweden | Skr65.63 Million |
|
InBioGen Co Ltd
KO:101140
|
Korea | ₩2.44 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down Optipharm.CO.LTD's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Optipharm.CO.LTD.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Optipharm.CO.LTD's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Optipharm.CO.LTD (2015–2025)
The table below shows the annual total liabilities of Optipharm.CO.LTD from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩15.37 Billion ≈ $10.42 Million |
-3.84% |
| 2024-12-31 | ₩15.98 Billion ≈ $10.83 Million |
+13.11% |
| 2023-12-31 | ₩14.13 Billion ≈ $9.58 Million |
+16.10% |
| 2022-12-31 | ₩12.17 Billion ≈ $8.25 Million |
+19.17% |
| 2021-12-31 | ₩10.21 Billion ≈ $6.92 Million |
+35.43% |
| 2020-12-31 | ₩7.54 Billion ≈ $5.11 Million |
+23.42% |
| 2019-12-31 | ₩6.11 Billion ≈ $4.14 Million |
-15.07% |
| 2018-12-31 | ₩7.20 Billion ≈ $4.88 Million |
+1.97% |
| 2017-12-31 | ₩7.06 Billion ≈ $4.78 Million |
-0.27% |
| 2016-12-31 | ₩7.08 Billion ≈ $4.79 Million |
-46.06% |
| 2015-12-31 | ₩13.12 Billion ≈ $8.89 Million |
-- |
About Optipharm.CO.LTD
Optipharm.CO.,LTD operates as a biomedical solution provider in South Korea. It also engages in animal disease diagnosis, animal medicine, bacteriophage, Medipig, xenogenic organs, VLP vaccines, xenotransplantation, and other optipharm products, as well as veterinary drug for feed additives and laboratory animal Medipig business. The company was formerly known as Optiparm Solution Co., Ltd. and c… Read more